IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 247 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $102,821 | -21.7% | 22,598 | +21.1% | 0.00% | – |
| Q2 2023 | $131,373 | +12.6% | 18,661 | -2.3% | 0.00% | – |
| Q1 2023 | $116,670 | -57.4% | 19,095 | -55.5% | 0.00% | – |
| Q4 2022 | $273,907 | -80.0% | 42,865 | -70.0% | 0.00% | -100.0% |
| Q3 2022 | $1,367,000 | -33.0% | 142,762 | -22.8% | 0.00% | 0.0% |
| Q2 2022 | $2,041,000 | -44.5% | 184,887 | -17.2% | 0.00% | -50.0% |
| Q1 2022 | $3,675,000 | -34.2% | 223,337 | -23.7% | 0.00% | -20.0% |
| Q4 2021 | $5,589,000 | -26.8% | 292,777 | -5.4% | 0.01% | -28.6% |
| Q3 2021 | $7,636,000 | -24.2% | 309,652 | -20.0% | 0.01% | -30.0% |
| Q2 2021 | $10,072,000 | -83.3% | 387,082 | -79.6% | 0.01% | -83.9% |
| Q1 2021 | $60,160,000 | -36.0% | 1,900,190 | -6.2% | 0.06% | -41.0% |
| Q4 2020 | $93,958,000 | +37.3% | 2,024,954 | -2.6% | 0.10% | +19.3% |
| Q3 2020 | $68,448,000 | +10.3% | 2,079,238 | -8.0% | 0.09% | +4.8% |
| Q2 2020 | $62,044,000 | -48.1% | 2,260,238 | -43.4% | 0.08% | -16.8% |
| Q1 2020 | $119,552,000 | +76.4% | 3,993,740 | +63.1% | 0.10% | +23.2% |
| Q4 2019 | $67,766,000 | +60.5% | 2,448,187 | +5.6% | 0.08% | +51.9% |
| Q3 2019 | $42,209,000 | -14.3% | 2,319,168 | +15.5% | 0.05% | -45.5% |
| Q2 2019 | $49,230,000 | +109.2% | 2,007,743 | -18.9% | 0.10% | +83.3% |
| Q1 2019 | $23,530,000 | -12.0% | 2,474,137 | -18.1% | 0.05% | -19.4% |
| Q4 2018 | $26,744,000 | -2.2% | 3,021,927 | +24.3% | 0.07% | +19.6% |
| Q3 2018 | $27,345,000 | -8.9% | 2,430,657 | +3.7% | 0.06% | -12.5% |
| Q2 2018 | $30,007,000 | -22.3% | 2,344,279 | +2.6% | 0.06% | -23.8% |
| Q1 2018 | $38,625,000 | +129.8% | 2,285,499 | +8.8% | 0.08% | +140.0% |
| Q4 2017 | $16,809,000 | -17.8% | 2,101,163 | -20.4% | 0.04% | -23.9% |
| Q3 2017 | $20,447,000 | +7.5% | 2,638,323 | +2.0% | 0.05% | +2.2% |
| Q2 2017 | $19,013,000 | – | 2,586,873 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 565,890 | $26,257,000 | 9.39% |
| Consonance Capital Management LP | 1,710,803 | $79,381,000 | 7.41% |
| GREAT POINT PARTNERS LLC | 917,427 | $42,569,000 | 6.91% |
| Avoro Capital Advisors LLC | 7,500,000 | $348,000,000 | 5.99% |
| Ghost Tree Capital, LLC | 500,000 | $23,200,000 | 5.17% |
| FRAZIER MANAGEMENT LLC | 1,312,999 | $60,923,000 | 4.69% |
| Perceptive Advisors | 9,166,304 | $425,316,000 | 4.56% |
| Ally Bridge Group (NY) LLC | 360,000 | $16,704,000 | 2.86% |
| Orbimed Advisors | 6,645,100 | $308,333,000 | 2.70% |
| ACUTA CAPITAL PARTNERS, LLC | 164,800 | $7,647,000 | 2.08% |